Related Experiment Videos
Allogeneic bone marrow transplantation: experience with 92 patients
G B Selby1, R A Saez, R B Epstein
1University of Oklahoma Health Sciences Center.
The Journal of the Oklahoma State Medical Association
|December 1, 1993
Summary
Allogeneic bone marrow transplantation (BMT) offers a cure for leukemia and lymphoma. Early BMT improves survival rates for patients with these hematologic malignancies and aplastic anemia.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment for hematologic malignancies and marrow failure.
- Ninety-two patients underwent BMT at Oklahoma Memorial Hospital over a decade.
- Treatments included various myeloablative preparative regimens.
Purpose of the Study:
- To evaluate the outcomes of allogeneic BMT in patients with leukemia, lymphoma, and aplastic anemia.
- To identify factors influencing mortality and survival.
- To develop guidelines for optimal BMT timing.
Main Methods:
- Retrospective analysis of 92 patients receiving allogeneic BMT.
- Categorization of patients by diagnosis: AML, CML, ALL, MDS, lymphomas, and aplastic anemia.
- Comparison of survival rates between standard and high-risk disease categories.
Main Results:
- Major causes of mortality included infections and disease relapse.
- Median survival for standard-risk AML, CML, and ALL was significantly better than high-risk.
- 71% of aplastic anemia patients achieved disease-free survival at 7.5 years.
Conclusions:
- Allogeneic BMT is effective for treating leukemia, lymphoma, and aplastic anemia.
- Early transplantation is associated with improved outcomes.
- Guidelines are established to encourage earlier BMT for better results in fatal hematologic disorders.